Risks and benefits of therapy with flumazenil (Anexate) in mixed drug intoxications.

Abstract

Flumazenil, the first specific benzodiazepine (BZD) antagonist, is one of the most innovative drugs to become available within the last few years. Flumazenil is indicated for the reversal of the centrally depressant effects of BZDs, in BZD-induced anaesthesia, in BZD sedation in intensive care and in patients comatose after drug overdoses including BZDs. A conference of experts experienced in the treatment of mixed drug overdoses by various means, including flumazenil, was held in order to try to reach a consensus regarding the safe use of flumazenil in this indication. From the knowledge and experience gained to date, it was concluded that flumazenil may be useful and safe in the treatment of suspected BZD and mixed drug overdoses, provided that the appropriate precautions are observed.

• Authors: E Geller, P Crome, M D Schaller, B Marchant, M Ectors, G Scollo-Lavizzari
• Journal: European neurology (Eur Neurol) Vol. 31 Issue 4 Pg. 241-50 ( 1991) ISSN: 0014-3022 [Print] Switzerland
• PMID: 1868866 (Publication Type: Consensus Development Conference, Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antidepressive Agents, Tricyclic
• Benzodiazepines
• Flumazenil

Topics

• Antidepressive Agents, Tricyclic (poisoning)
• Benzodiazepines (poisoning)
• Coma (drug therapy)
• Drug Interactions
• Drug Overdose (drug therapy, epidemiology)
• Flumazenil (therapeutic use)
• Humans
• Risk Factors